Financial Data and Key Metrics Changes - Adjusted Net Investment Income for Q1 2026 was $36.1 million, or $0.41 per share, up from $35.4 million or $0.40 per share in the prior quarter [4][19] - NAV per share decreased to $16.30 from $16.64 in the previous quarter due to unrealized depreciation on certain investments [19] - Adjusted total investment income decreased to $74.5 million from $76.9 million in the prior quarter, primarily due to lower interest income [19][20] Business Line Data and Key Metrics Changes - New funded investments totaled $314 million, up from $220 million in the prior quarter, reflecting a 42% sequential increase [6][16] - Non-accruals represented 3.1% of the total debt portfolio, stable sequentially and down nearly 85 basis points year-over-year [7][18] - The weighted average yield on debt investments was 9.3%, with first lien senior secured debt comprising 85% of the total portfolio [15][21] Market Data and Key Metrics Changes - Current trends in private credit show a bifurcation in the economy, with companies of scale having ample access to capital while struggling companies face limited access [9] - Spreads in private credit have bottomed out at SOFR +450-475 basis points, with expectations for stability in 2026 [10] - The median portfolio EBITDA increased from $150 million to $190 million sequentially, driven by new originations in larger companies [30] Company Strategy and Development Direction - The company remains focused on disciplined capital deployment into income-generating assets and reducing non-accruals to improve earnings power [5][6] - Oaktree is prioritizing loans to businesses with resilient models and defensible market positions, particularly in the software sector [10][12] - The company is monitoring the impact of AI on private credit and is cautious about potential disruptions in the software industry [11][38] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding middle-market M&A activity improving over the year, despite current lower volumes [9] - The company is focused on maintaining strong alignment with shareholders while navigating an evolving credit landscape [8] - Concerns were raised about the long-term refinanceability of loans in the software sector due to potential AI disruptions [38][39] Other Important Information - The company ended the quarter with over $576 million in available liquidity, including $81 million in cash [21][22] - The joint ventures held $511 million of investments, generating ROEs of 12% in aggregate [22] Q&A Session Summary Question: Can you provide insight into the portion of the portfolio that is underperforming? - Management indicated that underperforming assets include non-accruals and positions trading below par, with most below-par loans being public positions [24][25] Question: What drove the increase in median portfolio EBITDA? - The increase was primarily driven by new originations funded in the fourth quarter, which were larger companies, contributing to a mix shift [30] Question: Can you discuss the unrealized appreciation and markdowns in the quarter? - Pluralsight was the largest driver of markdowns, accounting for about 38% of the total mark, with some smaller marks in other private positions [32] Question: How is the company characterizing top-line growth and EBITDA trends in the software sector? - Management noted that it is too early to see performance degradation in software names, but concerns exist regarding long-term refinanceability due to AI risks [36][38]

Financial Data and Key Metrics Changes - Adjusted Net Investment Income for Q1 2026 was $36.1 million, or $0.41 per share, up from $35.4 million or $0.40 per share in the prior quarter [4][21] - NAV per share decreased to $16.30 from $16.64 in the previous quarter due to unrealized depreciation on certain investments [21] - Adjusted total investment income decreased to $74.5 million from $76.9 million, primarily due to lower interest income [22][23] Business Line Data and Key Metrics Changes - New funded investments totaled $314 million, up from $220 million in the prior quarter, reflecting a 42% sequential increase [6][17] - Non-accruals represented 3.1% of the total debt portfolio, stable sequentially and down nearly 85 basis points year-over-year [7][20] - The average all-in spread and yield of new private investments was 525 basis points and 9%, respectively [6] Market Data and Key Metrics Changes - Current trends in private credit show a bifurcation in the economy, with companies of scale having ample access to capital while struggling companies face limited access [9] - After the Fed rate cut in September, spreads in private credit have stabilized at SOFR plus 450-475 basis points [10] - The median portfolio EBITDA increased from $150 million to $190 million sequentially, driven by new originations in larger companies [34] Company Strategy and Development Direction - The company is focused on deploying capital into income-generating assets and reducing non-accruals to improve earnings power [5][6] - There is a commitment to disciplined underwriting and selectivity in investment opportunities, particularly in resilient market-leading businesses [11][12] - The company is monitoring the impact of AI on private credit and the broader economy, emphasizing the importance of execution and speed of adoption [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the stability of spreads in 2026 and the potential for increased middle-market M&A activity [10][12] - Concerns were raised about the long-term impact of AI on software companies, particularly regarding their refinanceability [40][42] - The company remains constructive on the long-term outlook for private credit, emphasizing the importance of active portfolio management [13] Other Important Information - The company declared a quarterly cash dividend of $0.40 per share, payable on March 31, 2026 [5] - The weighted average interest rate on debt outstanding was 6.1%, down from 6.5% in the prior quarter [24] - The company has approximately $576 million in liquidity, including $81 million in cash and $495 million in undrawn capacity on its credit facility [24] Q&A Session Summary Question: Can you provide insight into the portion of the portfolio that is underperforming? - Management indicated that underperforming assets include non-accruals and positions trading below par, with most below-par loans being public positions [27][28] Question: What drove the increase in median portfolio EBITDA? - The increase was primarily driven by new originations funded in the fourth quarter, which were larger companies, contributing to a mix shift [34][35] Question: Can you discuss the unrealized appreciation and markdowns in the quarter? - The largest driver of unrealized depreciation was Pluralsight, accounting for about 38% of the total mark, with some smaller marks in other private positions [36][37] Question: How does the company view top-line growth and EBITDA trends in the software sector? - Management believes it is too early to see performance degradation in software names, but concerns exist regarding long-term refinanceability due to potential AI disruption [40][42]

Financial Data and Key Metrics Changes - Adjusted Net Investment Income for Q1 2026 was $36.1 million, or $0.41 per share, a modest increase from $35.4 million or $0.40 per share in the prior quarter [3][20] - NAV per share decreased to $16.30 from $16.64 in the previous quarter due to unrealized depreciation on certain investments [20] - Adjusted total investment income decreased to $74.5 million from $76.9 million, primarily due to lower interest income [20][21] - Net leverage ratio increased to 1.07 times from 0.97 times, reflecting strong deployments during the quarter [22] Business Line Data and Key Metrics Changes - New funded investments totaled $314 million, up from $220 million in the prior quarter, indicating a 42% sequential increase [5][16] - Non-accruals represented 3.1% of the total debt portfolio, stable sequentially and down nearly 85 basis points year-over-year [5][19] - The weighted average yield on debt investments was 9.3%, with first lien senior secured debt comprising 85% of the total portfolio [15][22] Market Data and Key Metrics Changes - The private credit market is experiencing a bifurcation, with companies of scale and profitability having ample access to capital, while struggling companies face limited access [8] - Spreads in private credit have bottomed out at SOFR plus 450-475 basis points, with expectations for stability in 2026 [9][10] - Median portfolio EBITDA increased from $150 million to $190 million sequentially, driven by new originations of larger companies [33] Company Strategy and Development Direction - The company is focused on disciplined capital deployment into income-generating assets and reducing non-accruals to improve earnings power [4][5] - There is a commitment to strong alignment with shareholders while navigating an evolving credit landscape [6] - The company is prioritizing loans to businesses with resilient models and defensible market positions, particularly in the software sector [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the middle-market M&A activity improving over the year, despite current lower volumes [8] - The impact of AI on private credit is being closely monitored, with expectations of uneven outcomes across different players [10][11] - The company remains constructive on the long-term outlook for private credit, emphasizing disciplined underwriting and active portfolio management [12] Other Important Information - The company declared a quarterly cash dividend of $0.40 per share, payable on March 31, 2026 [4] - The company ended the quarter with over $576 million in available liquidity, including $81 million in cash [23] Q&A Session Summary Question: Can you provide insight into the portion of the portfolio that is underperforming? - Management indicated that underperforming assets include non-accruals and positions trading below par, with most stress observed in public positions [26][27] Question: What drove the increase in median portfolio EBITDA? - The increase was primarily driven by new originations funded in the fourth quarter, which were larger companies, contributing to a mix shift [33] Question: Can you elaborate on the unrealized appreciation and markdowns in the quarter? - The largest driver of unrealized depreciation was Pluralsight, accounting for about 38% of the total mark, with some smaller marks in other private positions [35] Question: How does the company view top-line growth and EBITDA trends in the software sector? - Management noted that it is too early to see performance degradation in software names, but concerns exist regarding long-term refinanceability due to potential AI disruption [39][40]

Group 1 - SanDisk (SNDK.US) will join the S&P 500 index on November 28, 2025, replacing IPG Photonics (IPG.US) [1] - PTC Therapeutics (PTCT.US) will replace SanDisk in the S&P SmallCap 600 index on the same date [1] - Upwork (UPWK.US) will take the place of Premier (PINC.US) in the S&P SmallCap 600 index on November 28 [1] Group 2 - Patient Square Capital's acquisition of Premier is expected to be completed by November 25 [1] - First Interstate BancSystem (FIBK.US) will replace Hanesbrands (HBI.US) in the S&P SmallCap 600 index on December 2 [1] - Gildan Activewear (GIL.US) is expected to complete its acquisition of Hanesbrands by December 1 [1]

Core Points - S&P Dow Jones Indices announced changes to the S&P 500 and S&P SmallCap 600 indices, effective November 28, 2025 [1][4] - The changes include the addition and deletion of several companies, reflecting ongoing market dynamics and corporate acquisitions [1][4] Group 1: S&P 500 Changes - Sandisk (SNDK) will be added to the S&P 500, replacing Interpublic Group (IPG), which is being acquired by Omnicom Group (OMC) [1][4] - The acquisition of Interpublic Group is expected to close soon, pending final conditions [4] Group 2: S&P SmallCap 600 Changes - Upwork (UPWK) will replace Premier Inc. (PINC) in the S&P SmallCap 600, with Premier being acquired by Patient Square Capital [1][4] - PTC Therapeutics (PTCT) will replace Sandisk in the S&P SmallCap 600, following Sandisk's addition to the S&P 500 [1][4] - First Interstate BancSystem (FIBK) will replace Hanesbrands (HBI) in the S&P SmallCap 600, with Gildan Activewear acquiring Hanesbrands [1][4]

Core Insights - Cumberland Pharmaceuticals Inc. has added its antibiotic Vibativ (telavancin) to a national group purchasing agreement with Premier, Inc., effective October 1, 2025, allowing Premier members to access special pricing and terms for the product [1][4] Group 1: Product Details - Vibativ is a once-daily, dual mechanism antibiotic effective against serious Gram-positive bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated skin and skin structure infections (cSSSI) [4][8] - The product is available in two packaging options: a standard 12-vial carton for high patient volume institutions and a new 4-vial Starter Pak designed for cost-effective therapy initiation and inventory management [2][4] Group 2: Market Context - Premier, a leading healthcare improvement company, unites approximately 4,350 U.S. hospitals and 325,000 other providers, enabling better care and outcomes at lower costs through integrated data and analytics, supply chain solutions, and consulting services [3] - The addition of Vibativ to Premier's offerings enhances access for healthcare providers, supporting both inpatient and outpatient settings [2][4] Group 3: Efficacy and Resistance - Vibativ was specifically designed to combat drug-resistant bacteria, with modifications that enhance its ability to penetrate bacterial cell walls and tissues, making it effective against infections that are difficult to treat [6][10] - Studies indicate that Vibativ maintains its potency against multidrug-resistant bacteria, demonstrating higher cure rates compared to vancomycin in treating HABP/VABP [7][10][11]

Core Viewpoint - Monteverde & Associates PC is investigating the proposed sale of Anywhere Real Estate Inc. to Compass Inc., questioning the fairness of the deal for shareholders [1]. Company Overview - Monteverde & Associates PC is a national class action securities firm based in the Empire State Building, New York City, recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1]. - The firm has a successful track record in recovering millions for shareholders through litigation in trial and appellate courts, including the U.S. Supreme Court [3]. Transaction Details - Under the proposed transaction, Anywhere shareholders will receive 1.436 shares of Compass Class A common stock for each share of Anywhere common stock [1]. - After the completion of the transaction, current Anywhere shareholders will own approximately 22% of the combined company [1].

Core Viewpoint - The Ademi Firm is investigating PROS for potential breaches of fiduciary duty and other legal violations related to its transaction with Thoma Bravo, which involves a significant financial arrangement for shareholders [1][2]. Group 1: Transaction Details - Shareholders of PROS will receive $23.25 per share in a transaction valued at approximately $1.4 billion [2]. - The transaction agreement imposes significant penalties on PROS if it accepts competing bids, which raises concerns about the board's fiduciary duties [2]. Group 2: Investigation Focus - The investigation by the Ademi Firm centers on the conduct of the PROS board of directors and whether they are adequately fulfilling their fiduciary responsibilities to all shareholders [2].

Group 1 - U.S. stocks showed mixed performance, with the Dow Jones index declining over 100 points on Monday [1] - PROS Holdings, Inc. shares surged 40% to $22.97 following the announcement of its acquisition by Thoma Bravo [1] - MBX Biosciences, Inc. saw a significant increase of 144% to $24.40 after its once-weekly Canvuparatide met primary endpoints in a Phase 2 trial [3] - Metsera, Inc. gained 62.8% to $54.25 amid reports of a near acquisition deal with Pfizer [3] - Anywhere Real Estate Inc. experienced a 57% rise to $11.13 due to a combination announcement with Compass in an all-stock transaction [3] - The ODP Corporation's shares increased by 33.6% to $27.82 after announcing a definitive agreement to be acquired by an affiliate of Atlas Holdings [3] - Banco BBVA Argentina S.A. shares rose 17.7% to $9.64 following U.S. Treasury Secretary Bessent's statement of support for Argentina [3] - Grupo Supervielle S.A. also saw a 16% increase to $5.83 under similar circumstances regarding U.S. support for Argentina [3] - Lumen Technologies, Inc. rose 12.5% to $6.43 after announcing significant progress in building infrastructure for the AI economy [3] - IREN Limited gained 10.7% to $42.88 after doubling its AI Cloud capacity to 23,000 GPUs [3]

Core Points - Metsera (Nasdaq: MTSR) is involved in a transaction with Pfizer, where shareholders will receive $47.50 per share, resulting in an enterprise value of approximately $4.9 billion [2][3] - The transaction agreement includes provisions that significantly limit competing offers for Metsera, imposing penalties if a competing bid is accepted [3] Investigation Details - The Ademi Firm is investigating potential breaches of fiduciary duty by Metsera's board of directors regarding their responsibilities to shareholders in light of the transaction with Pfizer [1][3] - The investigation focuses on whether the board is acting in the best interests of all shareholders, given the substantial benefits insiders will receive from change of control arrangements [2][3]